Pharmanutra SpA

Pharmanutra SpA

Health CarePharmaceuticals and Biotechnology
  • Price (EUR)63.80
  • Today's Change-1.40 / -2.15%
  • Shares traded9.76k
  • 1 Year change-3.92%
  • Beta0.2679
Data delayed at least 15 minutes, as of Sep 23 2022 16:35 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • PHN:MIL price rises above 200-day moving average to 65.60 at 10:56 BST
  • PHN:MIL price falls below 200-day moving average to 65.30 at 18:29 BST
  • PHN:MIL price moved over -1.18% to 67.20
  • PHN:MIL price falls below 50-day moving average to 67.20 at 10:03 BST

Key statistics

On Friday, Pharmanutra SpA (PHN:MIL) closed at 63.80, 27.60% above the 52 week low of 50.00 set on Mar 07, 2022.
52-week range
50.00Mar 07 202280.00Jan 05 2022
Markit short selling activity
Previous close65.20
Average volume10.06k
Shares outstanding9.68m
Free float3.39m
P/E (TTM)41.33
Market cap617.65m EUR
EPS (TTM)1.54
Annual div (ADY)0.71
Annual div yield (ADY)1.11%
Div ex-dateMay 02 2022
Div pay-dateMay 04 2022
Data delayed at least 15 minutes, as of Sep 23 2022 16:35 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.